v3.26.1
Segment Reporting - Schedule of Operating Expenses by Function (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Collaboration revenue $ 225,000 $ 0
Operating expenses:    
Research and development 14,843,000 21,076,000
General and administrative 5,447,000 6,462,000
Total operating expenses 20,290,000 27,538,000
Loss from operations (20,065,000) (27,538,000)
Other income, net:    
Interest income 793,000 635,000
Other income, net   39,000
Total other income, net 793,000 674,000
Net loss before income tax expense (19,272,000) (26,864,000)
Income tax expense 0 0
Net loss (19,272,000) (26,864,000)
Clinical    
Operating expenses:    
Research and development 5,376,000 5,947,000
Manufacturing (pre-commercial)    
Operating expenses:    
Research and development 3,465,000 5,447,000
Research    
Operating expenses:    
Research and development 2,958,000 5,919,000
Other    
Operating expenses:    
Research and development $ 3,044,000 $ 3,763,000